You are here

Article Text

Article menu
Download PDFPDF
Medicines update
Practical approach to managing metabolic bone disease of prematurity in the neonatal unit
  1. Chris Forster1,
  2. Shazia Hoodbhoy2,
  3. Catriona Macdougall2,
  4. Karen King3,
  5. Nigel Gooding4,
  6. Kimberly Mak5,
  7. Talat Mushtaq6
  1. 1 Neonatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  2. 2 Neonatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  3. 3 Dietetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  4. 4 Pharmacy, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  5. 5 Pharmacy, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  6. 6 Paediatric Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Dr Chris Forster, Neonatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; christopher.forster1{at}nhs.net

https://doi.org/10.1136/archdischild-2023-326100

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key points

    • Infants born <32 weeks or <1500 g are at risk of developing metabolic bone disease of prematurity (MBDP). Additional risk factors increase the need for regular screening.

    • Most babies with MBDP are calcium deficient. Parathyroid hormone (PTH) should be used to guide initial treatment and treatment response.

    • Calcium deficiency may occur even with normal serum calcium levels.

    • Phosphate deficiency may also occur and be co-existent with calcium deficiency. This is caused by the action of an elevated PTH and vitamin D deficiency.

    • Vitamin D deficiency can co-exist with calcium deficiency and concentration should be maintained >50 nmol/L.

    Introduction

    Metabolic bone disease of prematurity (MBDP) is a significant cause of morbidity within the neonatal population. However, there is uncertainty about which babies need screening and at what thresholds treatment is warranted, and the consensus approach to management has shifted in recent years. This has led to confusion surrounding timing of investigations, result interpretation and the optimum way to administer prescribed supplementations. Due to the lack of clear cut-offs and thresholds for investigation and management within current literature, a consensus approach at best can be recommended, with an aim to be practical and deliverable across the full range of neonatal services.

    Background

    MBDP affects 55% of infants <1000 g and 23% of those <1500 g, with increasing prevalence in those with additional risk factors such as diuretic or steroid use.1 During the final trimester of pregnancy, the placenta delivers significant concentrations of phosphate and calcium, and infants born prior to this are most at risk of developing deficiencies. Delivering comparative concentrations of electrolytes either enterally or within parenteral nutrition (PN) is challenging.2 MBDP is often diagnosed with radiographic changes between weeks 8 and 12 postnatally, though a reduction in bone density of 20–40% is required before this is apparent. Biochemical markers can …

    View Full Text

    Footnotes

    • Contributors CF is guarantor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.